Acadia Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
ALKERMES USD 292.72M 25.42M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Biogen USD 2.12B 106.5M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Corcept Therapeutics USD 153.8M 2.83M 2025-03
Cytokinetics USD 157.21M 1.24M 2025-03
Eisai JPY 189.26B 684M 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Incyte USD 847.73M 29.46M 2025-03
J&J USD 8.26B 10.37B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Prothena USD 67.02M 463K 2024-12
PTC Therapeutics USD 205.87M 69.79M 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
Ultragenyx Pharmaceutical USD 282.23M 4.92M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Acadia Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.